Drug-induced rheumatic syndromes.

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Medicine

Background:

• Drug-induced rheumatic syndromes have been documented for many years.
• Recent advancements in therapeutics have led to an increase in reported drug-associated rheumatic conditions.
• These syndromes are defined by their temporal relationship to drug initiation and resolution upon cessation.

Purpose of the Study:

• To review the associations between therapeutic agents and the development of rheumatic syndromes.
• To highlight the clinical presentations and typical course of drug-induced rheumatic conditions.
• To discuss the current understanding of the pathogenesis of these syndromes.

Main Methods:

• Literature review of reported cases and associations.
• Analysis of clinical features and outcomes.
• Discussion of pathogenetic mechanisms where known.

Main Results:

• Classic drug-induced syndromes commonly present as systemic lupus erythematosus or scleroderma-like conditions.
• Emerging therapeutic agents are increasingly associated with myositis and vasculitis.
• The underlying mechanisms for most drug-induced rheumatic syndromes are not yet fully elucidated.

Conclusions:

• Drug-induced rheumatic syndromes represent a significant clinical consideration.
• The spectrum of these conditions is evolving with new drug introductions.
• Further research is needed to understand the obscure origins of many drug-related rheumatic manifestations.